by Kamal Pratap Singh
There are few companies that can boast of being insightful, cost-effective in the first year of operations and Transcell is one such. At present, the group comprises of 40+ members including technologists and sales personnel taking inhouse research based service and product offerings to the market.
We arranged a talk with CEO of India’s pioneer biotech company built on stem cell based technologies at Hyderabad, India. She talks about current govt. regulations and business revenue generation of Stem cell industry. Recently govt. has also decided to frame Stem Cell therapy guidelines with high possibility to bring it in the gamut of healthcare industry.
The purpose of this talk is to share the experience of leaders of this niche biotech business and to help next generation entrepreneurs understand the nuances to take risks and stay motivated.
Brief profile of Founder of Tanscell – a stem cell based biotech organization
Subhadra Dravida, PhD is an experimentalist turned entrepreneur, Founder of Transcell group of biotech companies, www.transcellbio.science, based in Hyderabad, translating adult stem cell technologies prowess into clinical reality. Transcell is into biobanking, R&D of drug discovery (Oncology & Neuro) and regenerative medicine research (Muscular dystrophies & Periodontal diseases) based on adult stem cell technologies as platforms. She is a technocrat, successfully running the teams converting evidence based science to business opportunities with an intent to reach the patient communities. It is her chronic optimism; >13 yr of R&D experience from elite institutions of India, US and Canada; unwavering drive to crack the mysteries of cancers and neurodegenerative diseases using stem cells as tools (has patents to her credit) through her venture helping her to stand through the ups and lows of startup disease in India. It is a long journey and commitment in sciences that she has embraced while attempting to combine innovation in sciences and commerce to drive through Transcell from India that makes her stand stable in the striving ecosystem. Outside of her work, she likes to explore monasteries, treck, write her heart out and enjoys reading science fiction. The latest one that she read was Dan Brown’s Origin – Where did we come from; Where are we going? Dr. Dravida is a biologist by education with clinical informatics research experience having associated professionally with the University of North Carolina, USA, Ottawa Health Research Institute, Canada.
First of all how do you describe your venture – Transcell?
Transcell Biologics (Transcell) is a biotech company, founded on original research driven hypothesis i.e processing adult stem cells for the intended applications. The emphasis was on harvesting, processing and handling the right kind for the requirement. As a researcher and bench side scientist with my experience in the same domain of translational research, I could distinguish the domains of applications i.e regenerative medicine and drug discovery using stem cells as platforms. So, Transcell true to it’s theme of pluripotency and self renewing has built capacities and Intellectual property in Cancers, Neurodegenerative diseases, Muscular dystrophies and Periodontal diseases like indications based on in-house research findings on it’s proprietary platform technology (developed for both therapeutic and non-therapeutic applications).
All along, the Company has been creating the wealth of unique repository of India specific donor/patient sourced samples both for private and intended research use.
How is Transcell going to bring benefits to the biotech and healthcare industry in India?
We have been in the market, offering biobanking services for personalizing medicine along with some of the cell based products as prototype models to third party researchers in translational research and drug discovery programs. Our group has functional molecules as products in pipeline for Cancers and Neurodegenerative diseases with novel stem cell formulae in pre-clinical stage of development addressing Muscular dystrophies (Orphan disease) and Periodontal diseases.
BIOTECH EXPRESS magazine (BEM) is monthly news source of current and recent happenings of Global Bioscience and Life Science sector which includes but not limited to news and articles from Academics and Industry.
Click Image to read 5th Anniversary Issue …
AMONG MANY ACTIVITIES BRSI CONDUCT ANNUAL CONFERENCE ON THE RECENT HOT AND EMERGING TOPICS OF BIOTECHNOLOGY THUS FACILITATE DIRECT FLOW OF INFORMATION BETWEEN GLOBAL ACADEMIES AND INDUSTRIES.
BIOTECH EXPRESS Magazine (BEM) is providing latest Biotechnology and Allied Sciences news to Global community of Students, Researchers and Industry Professionals. BEM provides Current News, Opinions and Notices about Research, Hot Biotechnology Products, Biotechnology Jobs, Biotechnology Industry, Biotechnology Events, Biotechnology Business, Biotechnology R&D and Biotechnology Funding Grants from India and abroad.
E-mail to us at: firstname.lastname@example.org, email@example.com